Immutep Highlights Progress in TACTI-004 Phase III Cancer Trial
I'm PortAI, I can summarize articles.
Immutep Limited announced significant progress in its TACTI-004 Phase III trial for advanced non-small cell lung cancer, using eftilagimod alfa with KEYTRUDA® and chemotherapy. The trial has enrolled 289 patients globally, with regulatory approval in 27 countries and over 120 clinical sites activated. Key milestones include a futility analysis in early 2026 and completion of patient enrollment later that year. Despite financial challenges, Immutep's advancements in immunotherapy highlight its competitive positioning in the field.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments